Globalization of clinical trials: participation, development and future directions

Area of Science:

• Clinical Research
• Global Health Equity
• Evidence-Based Medicine

Background:

• Clinical trials are essential for evidence-based medicine, governed by regulations for ethical conduct and scientific rigor.
• Current clinical trials often fail to represent diverse global patient populations, particularly in developing nations.
• Developing countries frequently lack the necessary infrastructure, funding, and regulatory resources for robust clinical research, leaving prevalent diseases understudied.

Purpose of the Study:

• To examine the disparities in global clinical trial participation.
• To identify barriers contributing to the underrepresentation of developing nations in clinical research.
• To explore strategies for improving global clinical trial equity.

Main Methods:

• Review of existing literature on global clinical trial participation and disparities.
• Analysis of funding allocation in clinical research concerning developed versus developing nations.
• Identification of regulatory, infrastructural, and cultural factors affecting trial conduct in diverse settings.

Main Results:

• Global participation in clinical trials is highly unequal, with significant underrepresentation from developing nations.
• Funding for clinical trials does not align with the global disease burden, with most resources allocated to developed countries.
• Key barriers include stringent sponsor requirements, inadequate regulatory infrastructure, limited research training, and cultural/systemic factors.

Conclusions:

• Addressing global trial disparities necessitates understanding socioeconomic and cultural barriers.
• Streamlining guidelines can reduce operational obstacles without compromising scientific quality.
• Long-term strategies involving governments and industry are crucial for developing research infrastructure and training programs.